Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

NCT04090710 is registered in ClinicalTrials.gov with Ontario Clinical Oncology Group (OCOG) as lead sponsor.

NCT NCT04090710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04090710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Phase
Phase 2
Overall status
Completed
Start date
January 29, 2020
Completion date
June 30, 2026
Enrollment
66 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma